DOCSLIB.ORG

Benfotiaminebenfotiaminebenfotiamine by Gene Bruno, MS, MHS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Benfotiaminebenfotiaminebenfotiamine by Gene Bruno, MS, MHS SupplementScience BenfotiamineBenfotiamineBenfotiamine By Gene Bruno, MS, MHS enfotiamine is a lipid-soluble form classic deficiency disease “beriberi,” Benfotiamine for Diabetes of thiamine (vitamin B1) often characterized by:5 Benfotiamine has particularly valuable Bconsidered to be the most effec- • Peripheral neuropathy benefits to offer for individuals with dia- tive of the allithiamine group of natural- • Muscle pain and tenderness betes due to its unusual property of ly occurring, thiamine-derived com- • Rapid heart rate inhibiting three major pathways of dia- pounds, found in trace quantities in • Enlargement of the heart betes-induced vascular damage and roasted crushed garlic and other veg- • Edema (severe swelling due to neuropathy, and also having value in etables from the Allium genus (such as water retention) treating diabetic retinopathy and kidney onions, shallots and leeks). It is • Congestive heart failure damage. The three pathways include absorbed much better than water-solu- the hexosamine pathway, the advanced ble thiamine salts: maximum plasma Causes of Thiamine Deficiency glycation end product (AGE) formation levels of thiamine are about five times While thiamine deficiency is not common pathway and the diacylglycerol (DAG)- higher after benfotiamine, the bioavail- in the U.S., there are situations in which a protein kinase C (PKC) pathway.12 AGEs ability is at maximum about 3.6 times as deficiency may result from an increased are particularly nasty, so inhibition of high as that of thiamine hydrochloride requirement or excessive loss of this their formation is especially desirable. and better than other lipophilic thi- nutrient, as well as consumption of anti- amine derivates.1 thiamine factors. Situations in which Advanced Glycation End Product Before further exploring the research there is an increased need for thiamine (AGE) and benefits of benfotiamine, it is include strenuous physical exertion, AGEs are formed from glycosylated pro- important to understand the basics of fever, pregnancy, breast-feeding, adoles- teins, which in turn are formed when glu- thiamine since benfotiamine also per- cent growth and HIV-infection (with or cose has attached itself to protein. For forms the same functions. without AIDS).6 Excessive thiamine loss example, glucose can attach itself to the may be caused by chronic alcohol protein in red blood cells’ hemoglobin A Review of Thiamine abuse/alcoholism7, the use of diuretics8,9 and form glycosylated hemoglobin, also Thiamine was one of the first organic and hemodialysis.10 Anti-thiamin factors, called hemoglobin A1C, HbA1C, or just compounds to be recognized as a vita- including thiaminases which inactivate A1C for short. If this process continues to min. In its coenzyme form, thiamine is thiamin, can also promote a loss of this excess, one eventually ends up with required for a small number of very vitamin. Consuming large amounts of teaAGEs, which become permanent fixtures important enzymes that play critical and coffee (including decaffeinated), as in cells. AGE impregnated cells are very roles in the production of energy from well as habitually eating certain raw reactive and react with one another, and food, including the production of ATP.2 freshwater fish, raw shellfish and ferns other proteins. In the case of blood capil- It is also required for the synthesis of are at higher risk of thiamin deficiency laries, they can result in the walls of the the nucleic acids, DNA and RNA.3,4 A because these foods contain thiaminase capillaries thickening, eventually causing deficiency of thiamine may lead to the normally inactivated by heat in cooking.11 the vessels to be blocked off.13 38 VITAMIN RETAILER WWW.VITAMINRETAILER.COM I JULY 2012 “Benfotiamin is a particularly Essentially, AGE reactions create chemical rats, and completely prevented increas- handcuffs, which gum up proteins, deac- well-absorbed form of vitamin B1. es in AGE and PKU activity. This sug- tivate enzymes, trigger unhealthy bio- Double-blind research in gests that benfotiamine may help pre- chemical signaling in cells and damages diabetics demonstrated that oral vent or delay the progression of DNA, which contributes to the aging doses of 400 mg daily resulted in microvascular changes in patients with process. In a study on diabetic subjects, a statistically significant diabetic retinopathy. 600 mg of benfotiamine was supple- improvement in neuropathy score mented for 28 days. Blood was drawn Kidney Damage before and after treatment. The results in the treatment group Hemodialysis patients have an elevated were a significant reduction of intracellu- compared to placebo. The most level of damage to their genes in periph- lar glycoxidation and AGE formation.14 significant improvement reported eral blood lymphocytes (PBLs) and an was pain decrease in increased cancer incidence, possibly due Neuropathy to accumulation of toxins like AGEs. polyneuropathy (a type of Neuropathy is a collection of disorders that Since benfotiamine reduces AGE levels, peripheral neuropathy). Other occurs when nerves of the peripheral nerv- and since hemodialysis patients tend ous system are damaged. This is common- research has demonstrated toward vitamin B1 deficiency, researchers ly referred to as peripheral neuropathy statistically significant conducted two consecutive studies23 sup- (PN). PN usually causes pain and numb- effectiveness in reducing plementing hemodialysis patients with ness in the hands and feet. It can result diabetic neuropathy pain with benfotiamine. In both studies, benfoti- from traumatic injuries, infections, metabol- amine significantly lowered gene damage daily doses ranging between ic disorders and exposure to toxins. of PBLs in hemodialysis patients, inde- In a double-blind, randomized, place- 150-320 mg benfotiamine.” pendent of changes in plasma AGE lev- bo-controlled pilot study, 40 subjects with — A Guide to Complementary els. Since the antioxidative activity diabetic PN were given 400 mg benfoti- Treatments for Diabetes by Gene increased in treated patients, this may be amine daily or placebo for three weeks. Bruno (2010, Square One Publishers) the mechanism by which benfotiamine Results showed a statistically significant thy. During weeks five through eight, the ameliorated the DNA damage. improvement in the neuropathy score in dose of benfotiamine was reduced to Chronic renal insufficiency is when the the benfotiamine group compared to 120 mg daily. The results were that ben- filtering capacity of the kidneys are slow- placebo, with the most significant fotiamine led to significant improvement ly and gradually destroyed, and the kid- improvement being a decrease in pain.15 in the entire range of symptoms of alco- neys no longer have enough kidney Other research has demonstrated statisti- holic neuropathy. For some reason the function to maintain a normal state of cally significant effectiveness in reducing benfotiamine-alone group had better health. Many patients with chronic renal nerve pain with daily doses ranging results than the benfotiamine with vita- insufficiency have decreased erythrocyte between 150-320 mg benfotiamine.16 mins B6 and B12 group.19 In a Russian transketolase activity, which is a sign of In addition, several studies have shown study, 14 chronic alcoholic men with neu- thiamin deficiency. In clinical research24, beneficial results when using benfoti- ropathy were given 450 mg benfotiamine 20 patients with end-stage renal disease amine in combination with other B vita- daily for two weeks, followed by 300 mg where supplemented with a single 100 mins in the treatment of diabetic neu- daily for four weeks. The results showed a mg dose of benfotiamine or 100 mg of ropathy.17 In one study18, 30 subjects regression of neuropathy symptoms.20 thiamin nitrate. The results were that received 400 mg benfotiamine and 2,000 patients receiving the benfotiamine mcg of vitamin B12 daily for three weeks, Diabetic Retinopathy experienced higher concentrations of a followed by 150 mg benfotiamine and Diabetic retinopathy is the most com- thiamine coenzyme, as well as improved 750 mcg vitamin B12 daily for nine mon diabetic eye disease and a leading erythrocyte transketolase activity. The weeks, and another group of 15 subjects cause of blindness in American adults. It researchers concluded that benfotiamine received a B-complex vitamin supple- is caused by damage to the blood ves- may be of clinical benefit in patients with ment three months. The results were that sels of the retina. In a nine-month ani- end-stage renal disease. all patients treated with benfotiamine and mal study21, researchers administered vitamin B12 experienced significant relief benfotiamine to diabetic rodents to Conclusion in neuropathic pain and dramatic determine the potential for retinal pro- Clearly, benfotiamine offers important improvement in vibration perception tection. The results were that benfoti- benefits for individuals with diabetes. thresholds, while subjects receiving a B- amine promoted normal AGE levels in Perhaps most significant is its ability to complex vitamin experienced only slight, the animals’ retina, as well as several reduce AGE formation. This reduction non-statistically significant improvement. key metabolic parameters within the may, in turn, reduce the risk for devel- An eight-week, randomized, multi-cen- animals’ cells. In addition, benfotiamine oping many of the complications associ- ter, placebo-controlled, double-blind inhibited AGE-associated retinal dam- ated with diabetes, including neuropa- study compared the effect of 320 mg age. In an animal and in-vitro study22, thy, nephropathy and retinopathy. benfotiamine alone to 320 mg benfoti- researchers found that that supplemen- For a full list of references, visit amine with viamins B6 and B12 or place- tation with benfotiamine prevented www.vitaminretailer.com and view the bo in 84 alcoholic patients with neuropa- experimental diabetic retinopathy in online edition. JULY 2012 I WWW.VITAMINRETAILER.COM VITAMIN RETAILER 39.
Load more

Recommended publications
  • Multi Vitamin Formulations
    Multi Vitamin Formulations The gender-specific men’s and women’s multivitamins and the nerve tissue supplement contain ingredients in a form that the body can easily use, in the recommended daily amounts. These ingredients promote the health of the heart, brain, muscle, bone and other parts of the body by giving them the nutrients they need to function properly. This document goes into what is in each supplement, why those ingredients are present (and in what amounts) and what that particular ingredient does in the body. All ingredients in the supplements are natural and nontoxic, and help support good health. Ingredient review for the Multi Vitamin Supplement The broad-spectrum multivitamins were formulated for men and women according to the current knowledge of daily required amounts of nutrients, and the differences in need (as in iron) between men and women. The polyphenolics, probiotics, and secondary nutrients like carnitine and ubiquinone (CoQ10) were added to help supplement the daily diet, and to help support the tissue-support supplement that it is meant to be taken along with. The focus of this section reviewing the multi-vitamin offering is to understand how these ingredients work in the body to improve overall health, and how the formula compares to the new recommended daily intake values for food and dietary supplements in the updated 21CFR section 101.9 [1]. The ingredient list and dosages for the men’s and women’s multivitamins are described in the table below. Table 1: Overview of the gender specific Multi-Vitamin Ingredient
    [Show full text]
  • B Active™ B Active™
    ÎÇÊ*/Ê >iÀ £ÉÓ»Ê*ÀÌ>LiÊ À`iÀ £{Ê*/ -ÕL i>`}Ê B Active™ 2[X]XRP[0__[XRPcX^]b UÊ-Õ««ÀÌÊi>Ì ÞÊ,iëÃiÊÌÊ-ÌÀiÃÃÊ>`Ê>Ì}Õi UÊ-Õ««ÀÌÊ >ÀL Þ`À>ÌiÊiÌ>LÃÉ*ÃÃLÞÊ,i`ÕViÊ Ã ÎÉ{»Ê À`iÀ UÊ-Õ««ÀÌÊi>Ì ÞÊ iÀÛÕÃÊ-ÞÃÌiÉ`Ài>ÊÉÕiÊÕVÌ £ä*/Ê iÊ*ÕV ià UÊ-Õ««ÀÌÊi>Ì ÞÊÀiÊ >>Vi ÌiÌÊ Ý UÊ-Õ««ÀÌÊ >À`Û>ÃVÕ>ÀÊi>Ì Ê­VÕ`}ÊL`ÊViî Adbb2P]UXT[S<3 UÊ-Õ««ÀÌÊ }ÌÊ>`Êi>Ì ÞÊ` $$&($& B Active™ contains the entire spectrum of B vitamins to support a very wide range of bodily and stress-related functions. It features activated forms of vitamins B2, B6 and B12, with the addition of Benfotiamine, a patented, safe, fat-soluble, more physiologically-active form of thiamin.* BP]cP5T=<'&$& %%0eT]XSP0[STP All 360 Medicine® Formulas Meet or Exceed cGMP quality Standards 3XbRdbbX^] / iÊÜ>ÌiÀÃÕLiÊ ÊÛÌ>ÃÊ >ÛiÊÌÊLiÊ>LÃÀLi`ÊÊÌ iÊÃ>ÊÌiÃÌiÊ>`ÊÌ iÊ}ÊÌÊÌ iÊÛiÀÊÜ iÀiÊ Ì iÞÊ>ÀiÊLÌÀ>ÃvÀi`ÊÌÊÌ iÀÊ>VÌÛiÊViâÞiÊvÀðÊ>ÃÌÀÌiÃÌ>Ê>`ÉÀÊ i«>ÌVÊ«>ÀiÌÊ ÃÊiÞÊÌÊ>vviVÌÊ>LÃÀ«ÌÊ>`ÊÌ iÊ>VÌÛ>ÌÊ«ÀViÃðÊ*>Ã>Ê«ÞÀ`Ý>Êx½Ê« ë >ÌiÊ­*x*®ÊiÛiÃÊÜiÀiÊ vÕ`ÊÌÊLiÊÃ}vV>ÌÞÊÜiÀÊÌ >ÊÀ>ÊÊÓÓÊÕÌÊvÊΣʫ>ÌiÌÃÊÜÌ Ê«>Ài`ÊÛiÀÊvÕVÌ°£ ÊVÌÛiÊVÌ>ÃÊÛÌ>ÃÊ £]Ê Ó]Ê È]Ê>`Ê £ÓÊÊÌ iÀÊ« ÞÃ}V>Þ>VÌÛiÊvÀÊ>}ÊÌ iÊi>ÃiÀÊ ÌÊ >LÃÀLÊ >`Ê ºÀi>`ÞvÀÕÃi»°Ê ÀÊ iÝ>«i]Ê Ê «>ÌiÌÃÊ ÀiViÛ}Ê «ÞÀ`ÝiÊ ]Ê ÞÊ ÎÎÊ «iÀViÌÊ Àië`i`ÊÜÌ Ê>ÊVÀi>ÃiÊÊ«>Ã>Ê*x*ÆÊ ÜiÛiÀ]ÊÌ iÊiÛiÊVÀi>Ãi`ÊÊ>ÊvÊÌ iÊ«>ÌiÌÃÊÀiViÛ}Ê *x*°£ B Active™ *iÀ >«ÃÊ Ì iÊ ÃÌÊ ÌiÀiÃÌ}Ê }Ài`iÌÊ Ê Ì ÃÊ vÀÕ>Ê ÃÊ ivÌ>iÊ ­-LiâÞÌ >i "« ë >Ìi®]Ê>ÊÃ>vi]Êv>ÌÃÕLiÊ>>}ÊvÊÌ >iÊÌ >ÌÊÌÊÞÊÀ>ÃiÃÊL`Ê>`ÊÌÃÃÕiÊiÛiÃÊvÊ Ì >iÊ>ÌÊi>ÃÌÊvÛiÊÌiÃÊ } iÀÊÌ >ÊÌ iÊÜ>ÌiÀÃÕLiÊÃ>Ì]ÊLÕÌÊ>ÃÊÀi>ÃÊL>Û>>LiÊ>vÌiÀÊÌ iÊÀ>Ê >`ÃÌÀ>ÌÊÕ«ÊÌÊΰÈÊÌiÃÊ}iÀÊÌ >ÊÌ >iÊÃ>Ì°ÓÊ
    [Show full text]
  • The Absorption of Radioactive Sulphur -Labelled in Patients with Intestinal
    TITLE: The absorption of Radioactive Sulphur-labelled Thiamine Hydrochloride in Control Subjects and in Patients with Intestinal Malabsorption. SHORT TITI : A test for the Absorption of Thiamine in Man AUTHOR: A.D. THOMSON DEPARTMENT: From the University Department of Therapeutics, Royal Infirmary, Edinburgh. A Test for the Absorption of Thiamine in Man SUMMARY: (1) A method is described for investigating vitamin B1 absorption in man by measuring the urinary radioactivity during the 24 hours following an oral dose of radioactive 35S- thiamine which is given along with a parentergl injection of non-radioactive thiamine hydrochloride. (2) Analysis of small intestinal juice and characterisation of radioactive material in the urine indicate that the urine contains radioactive thiamine which was unchanged prior to absorption. (3) In control subjects, the major period of thiamine absorption occurred within the first 2 hours and practically all of the oral dose absorbed was excreted during the first 211. hours. (4) Eight patients with untreated primary malabsorptive disease (idiopathic steatorrhoea) showed a mean urinary excretion of radioactive thiamine sig- nificantly less than in the control group. The rate of excretion was markedly reduced but the period of maximal excretion occurred at approximately the same time as in control subjects. Thirteen patients with treated primary ma3absorp- tive disease showed no significant difference from the control group. (5) Ten patients who had undergone gastric surgery and two with resection of the terminal ileum excreted amounts which did not differ from the control group. Normal results were also found in four patients with pernicious anaemia. A Test for the Absorption of Thiamine in Man INTRODUCTION : Disease of the small intestine may cause impaired absorption of certain water -soluble vitamins.
    [Show full text]
  • The Effects of Long-Term Oral Benfotiamine Supplementation On
    Pathophysiology/Complications BRIEF REPORT The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes A 24-month, double-blind, randomized, placebo-controlled trial 1 1 DAVID A. FRASER, PHD KARI ANNE SVEEN, MD RESEARCH DESIGN AND 2 5,6 LIEN M. DIEP, MSC INGEBJØRG SELJEFLOT, PHD d 3 6,7 METHODS The study recruited 67 INGER ANETTE HOVDEN, MD, PHD KRISTIAN F. HANSSEN, MD, PHD 3,4 individuals with type 1 diabetes during KRISTIAN B. NILSEN, MD, PHD routine appointments at the Norwegian Diabetic Centre. Inclusion criteria were 1 2 d ) age 18 to 60 years (inclusive), )type1 OBJECTIVE To study the effects of long-term oral benfotiamine supplementation on pe- diabetes (.15-year duration), and 3) ripheral nerve function and soluble inflammatory markers in patients with type 1 diabetes. normo- or microalbuminuria. All patients RESEARCH DESIGN AND METHODSdThe study randomly assigned 67 patients with provided written informed consent. The type 1 diabetes to receive 24-month benfotiamine (300 mg/day) or placebo supplementation. study, which was approved by the re- Peripheral nerve function and levels of soluble inflammatory variables were assessed at baseline gional ethics committee and the Norwe- and at 24 months. gian Medicines Agency, was conducted RESULTSdFifty-nine patients completed the study. Marked increases in whole-blood con- as a parallel, randomized, double-blind, centrations of thiamine and thiamine diphosphate were found in the benfotiamine group (both placebo-controlled prospective trial of P , 0.001 vs. placebo). However, no significant differences in changes in peripheral nerve 24-month duration.
    [Show full text]
  • Benfotiamine, a Synthetic S-Acyl Thiamine Derivative, Has Different
    BMC Pharmacology BioMed Central Research article Open Access Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives Marie-Laure Volvert1, Sandrine Seyen1, Marie Piette2, Brigitte Evrard2, Marjorie Gangolf1, Jean-Christophe Plumier1 and Lucien Bettendorff*1 Address: 1Center for Cellular and Molecular Neurobiology, University of Liège, Avenue de l'Hôpital, 1, 4000 Liège, Belgium and 2Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Liège, Avenue de l'Hôpital, 1, 4000 Liège, Belgium Email: Marie-Laure Volvert - [email protected]; Sandrine Seyen - [email protected]; Marie Piette - [email protected]; Brigitte Evrard - [email protected]; Marjorie Gangolf - [email protected]; Jean- Christophe Plumier - [email protected]; Lucien Bettendorff* - [email protected] * Corresponding author Published: 12 June 2008 Received: 19 December 2007 Accepted: 12 June 2008 BMC Pharmacology 2008, 8:10 doi:10.1186/1471-2210-8-10 This article is available from: http://www.biomedcentral.com/1471-2210/8/10 © 2008 Volvert et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Lipid-soluble thiamine precursors have a much higher bioavailability than genuine thiamine and therefore are more suitable for therapeutic purposes. Benfotiamine (S-benzoylthiamine O- monophosphate), an amphiphilic S-acyl thiamine derivative, prevents the progression of diabetic complications, probably by increasing tissue levels of thiamine diphosphate and so enhancing transketolase activity.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Benfotiamine By: Gary E
    Benfotiamine By: Gary E. Foresman, MD 08/30/07 Benfotiamine is a lipid soluble form of thiamine (Vitamin B-1). The great advantage of benfotiamine comes from its lipid soluble state, which improves its absorption (bioavailability), making plasma levels of thiamine rise five times higher than when giving regular thiamine. Clinical trials have shown that despite the improved bioavailability, benfotiamine is significantly less toxic than common thiamine (which has no significant toxicity). This basically means you can’t develop benfotiamine toxicity. There are no drug interactions to be concerned about, and there are no known side-effects to this supplement. Furthermore, anyone taking a diuretic, birth control pills, or tricyclic antidepressants, should consider this supplement, as these drugs deplete B-1 from the body. Regular thiamine (B-1) has such limited bioavailability that many conditions keep our body from absorbing enough B-1 to adequately replete itself. This is where benfotiamine has its clinical utility. Most of the clinical research involved with benfotiamine focuses on its utility in preventing the complications of diabetes. But you could also consider benfotiamine important in anyone with insulin resistance or generally concerned about the aging process. You have heard me mention many times before the damage caused by advanced glycation end products (AGE). Succinctly, AGE’s are formed when blood sugar elevates. Abnormal elevations of blood sugar cause sugar to stick to proteins, causing them to malfunction (AGE). This is the primary cause of diabetic complications, especially in the eyes (retinopathy), kidneys (nephropathy), and nerves (neuropathy). It is also one of the primary causes of aging in general and even in non-diabetics associated with the age related changes involved in high blood pressure, vascular aging and Alzheimer’s.
    [Show full text]
  • Effects of the Red Garlic Extract for Anti-Obesity and Hypolipidemic in Obese Rats Induced High Fat Diet
    ISSN : 1225-9918 Journal of Life Science 2011 Vol. 21. No. 2. 211~220 DOI : 10.5352/JLS.2011.21.2.211 Effects of the Red Garlic Extract for Anti-Obesity and Hypolipidemic in Obese Rats Induced High Fat Diet Soo-Jung Lee1, Ra-Jeong Kim1, Ji-Hyun Ryu1, Jung-Hye Shin2, Min-Jung Kang2, In-Soo Kim1 and Nak-Ju Sung1,2* 1Department of Food Science and Nutrition, Institute of Agriculture and Life Sciences, Gyeongsang National University, Jinju 660-701, Korea 2Namhae Garlic Research Institute, Namhae 668-812, Korea Received December 22, 2010 /Accepted February 9, 2011 This study tested the anti-obesity and hypolipidemic effects of red garlic extract in obese rats induced by a high fat diet over a period of 4 weeks. Red garlic extract of 15 brix was added in 1, 3, 5 and 7% ratios in diets. The obesity index and body fat content significantly decreased in rats fed a diet with over 3% red garlic extract compared to the control group. There was no significant difference in weight of visceral and epididymal fat in rats fed red garlic extract. Total lipid and triglyceride lev- els in serum were significantly decreased in a dose-dependent manner, and AI and CRF also fell. ALT and AST activities in groups fed red garlic extract were decreased compared to the control group. Total lipid level in liver tissue of the groups fed 5-7% red garlic extract exhibited a significant de- crease compared to the control group. Total cholesterol and triglyceride levels in feces were sig- nificantly increased in rats fed a diet with over 5% red garlic extract.
    [Show full text]
  • Nerve Formula Research
    Nerve Formula Research Effectiveness of Different Benfotiamine Dosage Regimens in the Treatment of Painful Diabetic Neuropathy Winkler G, Pal B, Nagybeganyi E, Ory I, Porochnavec M, Kempler P. 2nd Department of Internal Medicine, Municipal St. John's Hospital, Budapest, Hungary. Arzneimittelforschung. 1999 Mar;49(3):220-4. Abstract The therapeutic effectiveness of a benfotiamine vitamin B combination, administered in high (4 x 2 capsules/day, = 320 mg benfotiamine/day) and medium doses (3 x 1 capsules/day), was compared to a monotherapy with benfotiamine (3 x 1 tablets/day, = 150 mg benfotiamine/day) in diabetic patients suffering from painful peripheral diabetic neuropathy (DNP). In a 6-week open clinical trial, 36 patients (aged 40 to 70 yrs) having acceptable metabolic control (HbA1c < 8.0%) were randomly assigned to three groups, each of them comprising 12 participants. Neuropathy was assessed by five parameters: the pain sensation (evaluated by a modified analogue visual scale), the vibration sensation (measured with a tuning fork using the Riedel-Seyfert method) and the current perception threshold (CPT) on the peroneal nerve at 3 frequencies: 5, 250 and 2000 Hz). Parameters were registered at the beginning of the study and at the end of the 3rd and 6th week of therapy. An overall beneficial therapeutic effect on the neuropathy status was observed in all three groups during the study, and a significant improvement in most of the parameters studied appeared already at the 3rd week of therapy (p < 0.01). The greatest change occurred in the group of patients receiving the high dose of benfotiamine (p < 0.01 and 0.05, resp., compared to the other groups).
    [Show full text]
  • Vitamins for Health VITAMINS for HEALTH by Danielle Laflash (With References from Nutrients for Neuropathy by John A
    Neuropathy Hope Hope through caring, support, research, education, and empowerment October 2015 Issue 10 A newsletter for members of Western Neuropathy Association (WNA) Volume 13 Vitamins For Health VITAMINS FOR HEALTH By Danielle LaFlash (with references from Nutrients for Neuropathy by John A. Senneff) WNA Support Groups Danielle is the incoming leader for the Redwood City Neuropathy Support Group. She has been active in the group for a while and Stan Pashote, who started the group and built it over the past years, is delighted she President’s Message is ready to take this role. Stan has been crossing the South Bay from his home in Fremont to lead this group and they will now have a leader that lives in the area. We are so appreciative of his determination to see an PN Literature Review active group on the Peninsula after a number of years of several others trying before he took the challenge. • The author (John A. Senneff) reviewed and summarized numerous clinical and laboratory studies in humans and animals. Severe Neuropathy • The emphasis in the chapter on vitamins relates only to those vitamins for which there is “credible Due To Inhalant Abuse scientific evidence that supplementation might or will provide neuropathic benefits.” In Adolescents From Pretoria Who Is This Information For? What Is the Best Way to Get Your Vitamins? Anyone who may have neurologic manifestations • Food is the best source of vitamins. Start by Food Interactions With of B vitamin deficiency. Possible symptoms include eating foods that are high in the nutrients we Medications weakness, poor balance, confusion, irritability, need.
    [Show full text]
  • YMC HPLC Columns Applications Notebook
    WA30000 HPLC Columns Applications Notebook Table of Contents Click on the items below to go directly to that section of the notebook. To Start a new search, click on Table of Contents Bookmark to the left YMC™ HPLC Column Quality Assurance............................................................2 Guide to YMC™ Part Numbering System ...........................................................3 YMC™ Column Selection Guide ....................................................................4-7 HPLC Troubleshooting and Reference Guide..................................................8-14 List of Applications..................................................................................15-20 1. Vitamins .....................................................................................21 2. Carbohydrates ............................................................................32 3. Nucleic Acids .............................................................................43 4. Amino Acids, Peptides, Proteins......................................................48 5. Organic Acids, Fatty Acid Derivatives .............................................60 6. Food Additives ............................................................................62 7. Natural Products ..........................................................................68 8. Steroids......................................................................................77 9. Drugs, Metabolites .......................................................................87
    [Show full text]
  • 197 a Acceptance and Commitment Therapy (ACT) , 75, 76, 78 Acetyl L -Carnitine (ALC) , 91, 129 ACT. See Acceptance and Commitm
    Index A Alpha-lipoic acid (ALA) , 91, 123 Acceptance and commitment therapy Alternative treatments (ACT) , 75, 76, 78 CAM, western society , 84 Acetyl L -carnitine (ALC) , 91, 129 mind-body therapies , 89–91 ACT. See Acceptance and commitment nutraceuticals therapy (ACT) ALA , 91 Acupuncture ALC , 91 alternative medicine techniques , 85 benfotiamine , 91 chemotherapy-induced peripheral fatty acids , 92 neuropathy , 89 vitamin B12 de fi ciency , 92 Chinese medicine , 84 zinc , 92 description , 66 osteopathic medicine , 83 DPN patients , 187–188 stimulation-based therapies moxibustion , 86 ( see Acupuncture) multicenter randomized controlled traditional medicine , 83 trial , 88–89 American Diabetes Association (ADA) , needles , 86 194–195 opioid receptors and endorphins , 85 Amyotrophy serotonin receptors , 85 asymmetrical proximal leg side effects , 88 weakness , 162 TCM , 86, 88 DPN , 162 timeline , 86, 87 ESR , 162 Acute painful neuropathy MRI, CT/ultrasound , 162 poor glycaemic control , 157 pain , 162 rapid glycaemic control (insulin neuritis) , type 1 and type 2 diabetic patients , 162 157–158 Anticonvulsants, DPN transient neuropathic syndromes , 157 adverse event related withdrawal , Advanced practice registered nurses 178–179 (APRNs) , 142 effects, quality of life and physical ALA. See Alpha-lipoic acid (ALA) functioning , 178 ALC. See Acetyl L -carnitine (ALC) ef fi cacy, individual , 178 Aldose reductase inhibitors (ARI) , 128 epilepsy , 177 Allodynia , 17–19 impacts , 179 Alpha-2-delta ligand agonist antiepileptic inhibition ,
    [Show full text]